Radiation Oncology | |
Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation | |
Jaime de la Garza2  Saé Muñiz-Hernández3  Diego G Zavala3  María D de la Mata4  Mónika Blake-Cerda4  Jesús Zamora4  Cynthia Villarreal-Garza3  Oscar Arrieta1  | |
[1] Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico;Clinic of Thoracic Oncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico;Experimental Oncology Laboratory, INCan, Mexico City, Mexico;Radio-Oncology Department, INCan, Mexico City, Mexico | |
关键词: survival; chemoradiotherapy; brain metastases; NSCLC; | |
Others : 1160932 DOI : 10.1186/1748-717X-6-166 |
|
received in 2011-07-29, accepted in 2011-11-25, 发布年份 2011 | |
【 摘 要 】
Background
Brain metastases occur in 30-50% of Non-small cell lung cancer (NSCLC) patients and confer a worse prognosis and quality of life. These patients are usually treated with Whole-brain radiotherapy (WBRT) followed by systemic therapy. Few studies have evaluated the role of chemoradiotherapy to the primary tumor after WBRT as definitive treatment in the management of these patients.
Methods
We reviewed the outcome of 30 patients with primary NSCLC and brain metastasis at diagnosis without evidence of other metastatic sites. Patients were treated with WBRT and after induction chemotherapy with paclitaxel and cisplatin for two cycles. In the absence of progression, concurrent chemoradiotherapy for the primary tumor with weekly paclitaxel and carboplatin was indicated, with a total effective dose of 60 Gy. If disease progression was ruled out, four chemotherapy cycles followed.
Results
Median Progression-free survival (PFS) and Overall survival (OS) were 8.43 ± 1.5 and 31.8 ± 15.8 months, respectively. PFS was 39.5% at 1 year and 24.7% at 2 years. The 1- and 2-year OS rates were 71.1 and 60.2%, respectively. Three-year OS was significantly superior for patients with N0-N1 stage disease vs. N2-N3 (60 vs. 24%, respectively; Response rate [RR], 0.03; p= 0.038).
Conclusions
Patients with NSCLC and brain metastasis might benefit from treatment with WBRT and concurrent thoracic chemoradiotherapy. The subgroup of N0-N1 patients appears to achieve the greatest benefit. The result of this study warrants a prospective trial to confirm the benefit of this treatment.
【 授权许可】
2011 Arrieta et al; licensee BioMed Central Ltd.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20150411084349974.pdf | 304KB | download | |
Figure 2. | 10KB | Image | download |
Figure 1. | 13KB | Image | download |
【 图 表 】
Figure 1.
Figure 2.
【 参考文献 】
- [1]Knights EM Jr: Metastatic tumors of the brain and their relation to primary and secondary pulmonary cancer. Cancer 1954, 7(2):259-65.
- [2]Galluzzi S, Payne PM: Brain metastases from primary bronchial carcinoma: a statistical study of 741 necropsies. Br J Cancer 1956, 10(3):408-14.
- [3]Newman SJ, Hansen HH: Proceedings: Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer 1974, 33(2):492-6.
- [4]Sorensen JB, Hansen HH, Hansen M, Dombernowsky P: Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988, 6(9):1474-80.
- [5]Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999, 43(4):795-803.
- [6]Schouten LJ, Rutten J, Huveneers HA, Twijnstra A: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002, 94(10):2698-705.
- [7]Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322(8):494-500.
- [8]Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, Tans JT, Lambooij N, Metsaars JA, Wattendorff AR, Brand R, Hermans J: The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994, 29(4):711-7.
- [9]Alexander E, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, Kooy HM, Loeffler JS: Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995, 87(1):34-40.
- [10]Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363(9422):1665-72.
- [11]Mekhail T, Sombeck M, Sollaccio R: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases: results of the EORTC 22952-26001 study. Curr Oncol Rep 2011, 13(4):255-8.
- [12]Magilligan DJ Jr, Duvernoy C, Malik G, Lewis JW Jr, Knighton R, Ausman JI: Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years' experience. Ann Thorac Surg 1986, 42(4):360-4.
- [13]Chidel MA, Suh JH, Greskovich JF, Kupelian PA, Barnett GH: Treatment outcome for patients with primary nonsmall-cell lung cancer and synchronous brain metastasis. Radiat Oncol Investig 1999, 7(5):313-9.
- [14]Bonnette P, Puyo P, Gabriel C, Giudicelli R, Regnard JF, Riquet M, Brichon PY: Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest 2001, 119(5):1469-75.
- [15]Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF, Pairolero PC: Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg 2001, 122(3):548-53.
- [16]Louie AV, Rodrigues G, Yaremko B, Yu E, Dar AR, Dingle B, Vincent M, Sanatani M, Younus J, Malthaner R, Inculet R: Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer. Clin Lung Cancer 2009, 10(3):174-9.
- [17]Hu C, Chang EL, Hassenbusch SJ, Allen PK, Woo SY, Mahajan A, Komaki R, Liao Z: Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 2006, 106(9):1998-4.
- [18]Flannery TW, Suntharalingam M, Regine WF, Chin LS, Krasna MJ, Shehata MK, Edelman MJ, Kremer M, Patchell RA, Kwok Y: Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys 2008, 72(1):19-23.
- [19]Greene FL, American Joint Committee on Cancer, American Cancer Society: AJCC Cancer Staging Manual. 6th edition. New York: Springer-Verlag; 2002.
- [20]Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999, 45(2):427-34.
- [21]Burt M, Wronski M, Arbit E, Galicich JH: Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff. J Thorac Cardiovasc Surg 1992, 103(3):399-410. discussion 10-1
- [22]Salvati M, Cervoni L, Tarantino R, Puzzilli F, Delfini R: Solitary cerebral metastasis as first symptom of lung cancer. Neurochirurgie 1994, 40(4):256-8.
- [23]Modi A, Vohra HA, Weeden DF: Does surgery for primary non-small cell lung cancer and cerebral metastasis have any impact on survival? Interact Cardiovasc Thorac Surg 2009, 8(4):467-73.
- [24]Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009, 374(9687):379-86.
- [25]van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, Tjan-Heijnen VC, Biesma B, Debruyne C, van Zandwijk N, Splinter TA, Giaccone G: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007, 99(6):442-50.
- [26]Ampil F, Caldito G, Milligan S, Mills G, Nanda A: The elderly with synchronous non-small cell lung cancer and solitary brain metastasis: does palliative thoracic radiotherapy have a useful role? Lung Cancer 2007, 57(1):60-5.
- [27]Mussi A, Pistolesi M, Lucchi M, Janni A, Chella A, Parenti G, Rossi G, Angeletti CA: Resection of single brain metastasis in non-small-cell lung cancer: prognostic factors. J Thorac Cardiovasc Surg 1996, 112(1):146-53.
- [28]Iwasaki A, Shirakusa T, Yoshinaga Y, Enatsu S, Yamamoto M: Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor. Eur J Cardiothorac Surg 2004, 26(3):488-93.
- [29]Wronski M, Burt M: Results and prognostic factors of surgery in the management of non-small cell lung cancer with solitary brain metastasis. Cancer 1992, 70(7):2021-3.
- [30]Abrahams JM, Torchia M, Putt M, Kaiser LR, Judy KD: Risk factors affecting survival after brain metastases from non-small cell lung carcinoma: a follow-up study of 70 patients. J Neurosurg 2001, 95(4):595-600.
- [31]Moazami N, Rice TW, Rybicki LA, Adelstein DJ, Murthy SC, DeCamp MM, Barnett GH, Chidel MA, Suh JH, Blackstone EH: Stage III non-small cell lung cancer and metachronous brain metastases. J Thorac Cardiovasc Surg 2002, 124(1):113-22.
- [32]Girard N, Cottin V, Tronc F, Etienne-Mastroianni B, Thivolet-Bejui F, Honnorat J, Guyotat J, Souquet PJ, Cordier JF: Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases. Lung Cancer 2006, 53(1):51-8.
- [33]Wronski M, Arbit E, Burt M, Galicich JH: Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991. J Neurosurg 1995, 83(4):605-16.
- [34]Furák J, Troján I, Szöke T, Agócs L, Csekeö A, Kas J, Svastics E, Eller J, Tiszlavicz L: Lung cancer and its operable brain metastasis: survival rate and staging problems. Ann Thorac Surg 2005, 79(1):241-7. discussion 41-7
- [35]Yoshinaga Y, Enatsu S, Iwasaki A, Shirakusa T: Surgical treatment for primary non-small cell lung cancer with synchronous brain metastases. [in Japanese]. Kyobu Geka 2006, 59(1):41-5.
- [36]Arrieta O, Saavedra-Perez D, Kuri R, Aviles-Salas A, Martinez L, Mendoza-Posada D, Castillo P, Astorga A, Guzman E, De la Garza J: Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. (Abstract). BMC Cancer 2009, 9:119. BioMed Central Full Text
- [37]Fischer B, Lassen U, Mortensen J, Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, Ravn J, Clementsen P, Høgholm A, Larsen K, Rasmussen T, Keiding S, Dirksen A, Gerke O, Skov B, Steffensen I, Hansen H, Vilmann P, Jacobsen G, Backer V, Maltbaek N, Pedersen J, Madsen H, Nielsen H, Højgaard L: Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009, 361(1):32-9.